Soon, you may know exactly when your brain may start to fail. While it may sound like a plot from a movie, a new "biological clock" developed by scientists may make it a reality. Researchers at the Washington University School of Medicine in St Louis have made it possible to just analyse a blood sample and thereafter estimate when a person’s Alzheimer’s symptoms would begin - often years before the first signs of forgetfulness appear.
The study, published in the journalNature Medicine, focuses on a specific protein in the blood known as p-tau217, which serves as a marker for the "plaques and tangles", known as amyloid and tau, that slowly accumulate in the brains of Alzheimer’s patients. According to the scientists, the protein levels could help to predict the onset of cognitive decline within a range of 3 to 3.7 years.
“Amyloid and tau levels are similar to tree rings; if we know how many rings a tree has, we know how many years old it is,” Kellen Petersen, lead author and instructor in neurology, said in a news release. “It turns out that amyloid and tau also accumulate in a consistent pattern, and the age at which they become positive strongly predicts when someone is going to develop Alzheimer’s symptoms,” he added.
The team said they analysed more than 600 adults, whose average age was 67.7, meaning half were older, half younger. The findings of the study revealed that the brain’s ability to handle amyloid and tau proteins changes as people age.
Scientists also gave an example of a 60-year-old with elevated protein levels who did not show Alzheimer’s symptoms for another 20 years. But an 80-year-old with the same levels saw symptoms in just a decade, which means that older brains have less reserve to fight off the damage.
At present, identifying Alzheimer’s risk often requires expensive brain scans or invasive spinal taps. However, this new blood test offers a quicker, less costly, more accessible alternative that could change how doctors and scientists approach the disease.
The test is used today mostly in research settings. “In the near term, these models will accelerate our research and clinical trials,” said Suzanne Schindler, senior author and associate professor of neurology. “Eventually, the goal is to be able to tell individual patients when they are likely to develop symptoms, which will help them and their doctors to develop a plan to prevent or slow symptoms,” she added.
Also read:Why Your Brain Needs Real Breaks: The Science of Deep Rest Explained
The development of reliable blood-based biomarkers could mark a major shift in how Alzheimer’s disease is managed. Instead of diagnosing dementia after symptoms significantly impair daily life, doctors may soon identify high-risk individuals years earlier.
Early detection does not mean cure — there is currently no cure for Alzheimer’s disease. However, identifying risk sooner could allow patients to adopt brain-healthy habits, manage cardiovascular risk factors, and participate in emerging treatment trials.
Source: India Latest News, Breaking News Today, Top News Headlines | Times Now
